Brief: Pieris Pharmaceuticals Inc Received Notice Of Delisting From Nasdaq
May 19 (Reuters) - Pieris Pharmaceuticals Inc PIRS.O :
* PIERIS PHARMACEUTICALS INC- ON MAY 15, CO RECEIVED NOTICE
OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Further company coverage: PIRS.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs